CMV reactivation after CAR-T cell therapy for leukemia or lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study looks at how often a common virus called CMV reactivates—meaning it becomes active again—in patients who receive CAR-T cell treatment for leukemia or lymphoma. It aims to understand the risks and help doctors better manage care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are of any age: either a child (1 to 18 years old) or an adult.
- You have received or will receive CAR-T cell therapy for a type of blood cancer that has come back or is hard to treat.
- You have been infected with CMV in the past (your body has antibodies against it).
- If you are joining the part that looks back at past data, you (or your parents, if you are a child) must agree to take part.
- If you are joining the part that follows you forward, you (or your parents, if you are a child) must sign a consent form.
- You must have medical insurance in France (or be covered by the French health system).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This study looks at how often a common virus (CMV) becomes active again in children after a stem cell transplant from a donor. It will help doctors understand more about this risk and how to manage it.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD4 on CMML cells. It is for people whose CMML has come back or not responded to standard treatment.
This trial tests if a drug called letermovir can safely prevent CMV (a common virus) from reactivating after you receive CAR T-cell therapy (Axi-cel). It may help reduce infections and side effects.
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.